Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ME2 | P23368 | 7/20 | 0.43 |
| ▸ | ME1 | P48163 | 7/20 | 0.43 |
| ▸ | ME3 | Q16798 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KRAS | P01116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17634307 | 0.83 | JAK3 (0.47) | KDM4ELMNAGAAMAPTME2 | |
| SCHEMBL17640815 | 0.81 | JAK3 (0.45) | KDM4ELMNAGAAMAPTME2 | |
| SCHEMBL17640813 | 0.77 | JAK3 (0.45) | KDM4ELMNAGAAMAPTME2 | |
| SCHEMBL25045164 | 0.76 | MAPT (0.56) | KDM4ELMNAGAAMAPTALDH1A1 | |
| SCHEMBL17640832 | 0.72 | CYP17A1 (0.47) | KDM4ELMNAGAAMAPTME2 | |
| SCHEMBL22174993 | 0.72 | AKR1C3 (0.59) | KDM4ELMNAGAAMAPTALDH1A1 | |
| SCHEMBL20456544 | 0.69 | MAPT (0.63) | KDM4ELMNAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL17640831 | 0.69 | KRAS (0.52) | BCL2A1KMT2AKRAS | |
| SCHEMBL17640834 | 0.69 | LMNA (0.48) | LMNAMAPTALDH1A1SMN1; SMN2JAK3 | |
| SCHEMBL21583811 | 0.69 | AKR1C3 (0.61) | LMNAMAPTME2ME1ME3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197870-B1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3197870-B1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20180141927-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-05-24 | — | — | US | disclosed |
| US-20180141927-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-05-24 | — | — | US | disclosed |
| US-9862701-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2016-04-21 | — | — | US | disclosed |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2016-04-21 | — | — | US | disclosed |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2016-04-21 | — | — | US | disclosed |
| WO-2016049524-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | KDM4E 3508/4885LMNA 603/4885GAA 2777/4885 |
| US-20180141927-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | KDM4E 3508/4885LMNA 603/4885GAA 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.